Axcella Health Inc. AXLA
We take great care to ensure that the data presented and summarized in this overview for Axcella Health Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding AXLA
View allLatest Institutional Activity in AXLA
Top Purchases
Top Sells
About AXLA
Axcella Health Inc. operates as a clinical stage biotechnology company in the United States. The company treats complex diseases and enhances health using endogenous metabolic modulator compositions. Its lead product candidates include AXA1665, which is in Phase 2 clinical trial for the reduction in risk of overt hepatic encephalopathy recurrence; and AXA1125 that is in Phase 2b clinical trial for treating non-alcoholic steatohepatitis, as well as in Phase 2a clinical trial for Long COVID therapy for patients. The company was formerly known as Newco LS16, Inc. and changed its name to Axcella Health Inc. in June 2016. Axcella Health Inc. was incorporated in 2008 and is based in Cambridge, Massachusetts.
Insider Transactions at AXLA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 01
2023
|
Margaret Koziel Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
679
-2.66%
|
$0
$0.58 P/Share
|
|
Feb 10
2023
|
Paul Fehlner SVP & Chief Legal Officer |
BUY
Open market or private sale
|
Direct |
5,221
+8.25%
|
$0
$0.66 P/Share
|
|
Oct 19
2022
|
William Hinshaw President & CEO |
SELL
Open market or private sale
|
Direct |
16,000
-16.32%
|
$16,000
$1.56 P/Share
|
|
Oct 17
2022
|
William Hinshaw President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+33.78%
|
-
|
|
Oct 13
2022
|
Societe Des Produits Nestle S.A. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
3,658,536
+24.78%
|
$3,658,536
$1.64 P/Share
|
|
Oct 13
2022
|
Flagship Ventures Fund Iv General Partner LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
10,383,760
+22.62%
|
$10,383,760
$1.64 P/Share
|
|
Sep 06
2022
|
Margaret Koziel Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
547
-2.1%
|
$1,094
$2.52 P/Share
|
|
Jun 01
2022
|
Margaret Koziel Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
590
-2.21%
|
$1,180
$2.01 P/Share
|
|
May 19
2022
|
David R Epstein Director |
BUY
Grant, award, or other acquisition
|
Direct |
47,059
+18.32%
|
-
|
|
Mar 18
2022
|
David R Epstein Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,535
+0.93%
|
-
|
|
Mar 16
2022
|
Robert Crane Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
39,267
+50.0%
|
$39,267
$1.91 P/Share
|
|
Mar 16
2022
|
David R Epstein Director |
BUY
Open market or private purchase
|
Direct |
26,178
+13.97%
|
$26,178
$1.91 P/Share
|
|
Mar 16
2022
|
Paul Fehlner SVP & Chief Legal Officer |
BUY
Open market or private purchase
|
Direct |
10,471
+33.48%
|
$10,471
$1.91 P/Share
|
|
Mar 16
2022
|
William Hinshaw President & CEO |
BUY
Open market or private purchase
|
Direct |
13,089
+21.42%
|
$13,089
$1.91 P/Share
|
|
Mar 16
2022
|
Flagship Ventures Fund Iv General Partner LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
6,319,371
+29.61%
|
$6,319,371
$1.91 P/Share
|
|
Mar 16
2022
|
Societe Des Produits Nestle S.A. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
3,141,361
+29.67%
|
$3,141,361
$1.91 P/Share
|
|
Mar 01
2022
|
Margaret Koziel Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
553
-2.03%
|
$553
$1.86 P/Share
|
|
Feb 18
2022
|
David R Epstein Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,534
+1.12%
|
-
|
|
Jan 31
2022
|
William Hinshaw President & CEO |
SELL
Open market or private sale
|
Direct |
16,590
-33.18%
|
$16,590
$1.65 P/Share
|
|
Jan 28
2022
|
William Hinshaw President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+50.0%
|
-
|